Review: NMNAT-1 and NAD⁺ in neuroprotection and aging
This review examines NMNAT-1, the main nuclear enzyme for NAD⁺ synthesis, and its debated role in brain aging and neurodegeneration. Human genetic evidence is strong for inherited retinal degeneration, but links to broader brain aging rest mainly on preclinical or indirect evidence, and no human trial has shown efficacy for an NMNAT-1-directed neurological therapy. [1]
Automatic summary · not editorially reviewed
The key findings
NMNAT-1 catalyzes the final step of NAD⁺ biosynthesis and is the major nuclear isoform of the mammalian NMNAT family. [1]
Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited retinal degeneration, while links to broader brain aging are mainly preclinical, preliminary or indirect. [1]
No human trial has yet established efficacy for an NMNAT-1-directed neurological therapy. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Not specified in the abstract; the review covers NMNAT-1 biology in mammalian cells and models, inherited retinal degeneration, brain aging, selected neurodegenerative models and glioma biology.
- Summary based on
- Study abstract
- Original publication
- August 21, 2026
NMNAT-1 as nuclear NAD⁺ enzyme
The review describes NAD⁺ as a metabolic cofactor and signaling molecule involved in redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation and neuronal maintenance. Age-associated NAD⁺ decline has been linked to brain aging and neurodegenerative disorders, but the authors note that the causal node and the limiting compartment differ between tissues and disease states. NMNAT-1 catalyzes the final step of NAD⁺ biosynthesis and is the major nuclear form of the mammalian NMNAT family. The review sets out to distinguish nuclear NAD⁺ supply, engineered axonal protection, adjacent NAD⁺ interventions and possible non-catalytic protection.
Supporting source [1]
Retinal evidence versus broader brain claims
According to the review, direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited retinal degeneration. By contrast, evidence linking endogenous NMNAT-1 to broader brain aging or sporadic neurodegeneration is described as mainly convergent preclinical, preliminary or indirect. Biochemical and Drosophila studies suggest possible chaperone-like and proteostasis-supporting functions, but the review states that a separable NAD⁺-independent function of endogenous mammalian NMNAT-1 has not yet been established in vivo. The authors also discuss how NMNAT-1 dysfunction may contribute to aging-associated genomic instability, neuroinflammation, synaptic impairment, retinal degeneration, selected neurodegenerative models and glioma biology.
Supporting source [1]
Therapeutic strategies lack human efficacy data
The review evaluates therapeutic strategies targeting NMNAT-1 and NAD⁺ pathways. It notes that no human trial has yet established efficacy for an NMNAT-1-directed neurological therapy. The authors argue that a compartment-aware and evidence-stratified view is essential for translating NMNAT-1 biology into interventions for age-related neural disease. This is a review abstract; the full text was not reviewed here, so details of the included studies, their designs and sample sizes are not reported in the supplied text.
Supporting source [1]
How to interpret this
This is a review abstract; the full text was not reviewed. The abstract reports no study designs, sample sizes or follow-up data for the cited work. Human genetic evidence is limited to inherited retinal degeneration; broader brain-aging and neurodegeneration links are described as preclinical, preliminary or indirect, and no human trial has established efficacy for an NMNAT-1-directed neurological therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Sun Y, Li B, Qian Z. · europepmc.org · August 21, 2026